Cargando…

Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer

Multitargeted antiangiogenic drugs have demonstrated significant antitumor activity against a variety of solid tumors. Anlotinib, a novel oral multitargeted antiangiogenic tyrosine kinase inhibitor, was approved as a third-line treatment for advanced NSCLC in China. However, predictive biomarkers ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Shencun, Cheng, Wanwan, Zhang, Meiling, Yang, Rusong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354100/ https://www.ncbi.nlm.nih.gov/pubmed/32753898 http://dx.doi.org/10.2147/OTT.S257052

Ejemplares similares

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment
por: Dong, Changqing, et al.
Publicado: (2022)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
por: Qi, Wenbo, et al.
Publicado: (2023)

Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
por: Zhang, Yuhai, et al.
Publicado: (2022)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
por: Feng, Shao, et al.
Publicado: (2022)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
por: Lee, Eung Bae, et al.
Publicado: (2010)

Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment
por: Cheng, Wanwan, et al.
Publicado: (2021)

TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study
por: Hao, Fang, et al.
Publicado: (2022)

A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis
por: Cheng, Wanwan, et al.
Publicado: (2022)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

Polymorphisms in Apoptosis-Related Genes and TP53 Mutations in Non-Small Cell Lung Cancer
por: Bae, Eun Young, et al.
Publicado: (2011)

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
por: Fan, Zhisong, et al.
Publicado: (2022)

Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer
por: Li, Ming, et al.
Publicado: (2016)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
por: Li, Yu-Feng, et al.
Publicado: (2022)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non–Small Cell Lung Cancer
por: Zhu, Lihuan, et al.
Publicado: (2023)

Non-invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non-small cell lung cancer
por: Wu, Zhen, et al.
Publicado: (2019)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab
por: Cai, Zhihui, et al.
Publicado: (2020)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
por: Liu, Yutao, et al.
Publicado: (2019)

Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
por: Samulin Erdem, Johanna, et al.
Publicado: (2016)

A Novel TP53 Gene Mutation Sustains Non-Small Cell Lung Cancer through Mitophagy
por: Wang, Yuanli, et al.
Publicado: (2022)

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non‐small cell lung cancer
por: Jiang, Wensheng, et al.
Publicado: (2022)

Bronchoscopic intratumoural therapies for non-small cell lung cancer
por: DeMaio, Andrew, et al.
Publicado: (2020)

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
por: Kron, A, et al.
Publicado: (2018)

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2021)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
por: Li, Huiying, et al.
Publicado: (2019)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhang, Kun, et al.
Publicado: (2020)

Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis
por: Yu, Guocan, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer
por: Chen, Jingyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ed0umbcqkfle599q7b2599tarm